BC Extra | Sep 26, 2019
Company News

Blade eyeing fibrosis combos with acquisition of PharmAkea-spinout

Blade is adding to its fibrosis pipeline with the acquisition of PharmAkea-spinout ATXco Inc. and its autotaxin inhibitor PAT-409. President and CEO Wendye Robbins said PAT-409 is complementary to Blade Therapeutics Inc.’s BLD-2660, a calpain...
Items per page:
1 - 1 of 1